Shots: Yuhan to receive $40M as upfront & near-term payment and up to $830M milestones and royalties on sales. BI focuses to develop NASH treatment targeting key drivers of the […]readmore
Tags : Boehringer Ingelheim
Shots: The Fast Track designation follows two P-III EMPEROR-Reduced & EMPEROR-Preserved studies assessing Empagliflozin (qd) vs PBO in 8,500+ patients with heart failure with reduced & preserved ejection fraction, both […]readmore
Shots: (NCT01243424) study results involve assessing of Tradjenta (5mg, qd) vs glimepiride in patients with type2 diabetes across 43 countries for 6+years The CAROLINA study resulted in meeting its 1EPs […]readmore
Shots: AbbVie has resolved the Humira litigation with BI, granting BI non-exclusive rights to BI for Humira’s IPR in the US BI will pay royalties for licensing HUMIRA patents and […]readmore
Shots: Boehringer Ingelheim (BI) and Amal Therapeutics enter into a clinical research agreement to conduct P-Ib KISIMA-01 study assessing Amal’s ATP128 and BI’s BI754091 with microsatellite stable (MSS) patients with […]readmore
Shots: PureTech to receive $26M as an upfront including research funding & preclinical milestone, $200M as development and commercial milestones and royalties on sales. Boehringer to develop immune-oncology candidates after […]readmore
Shots: Boehringer Ingelheim acquires ICD Therapeutics in all stock transaction, to utilize ICD’s MacroDel biologics-delivery platform to develop oncology therapies for intracellular delivery of macromolecules (peptides and proteins) The focus […]readmore
Shots: Philogen collaborates with J&J to discover & develop therapies utilizing Philochem’s technology (a Swizz subsidiary of Philogen) for serious conditions Philogen signs a development and commercialization agreement with Celgene […]readmore
Shots: BI & BioMed X enters into an agreement to develop strategies for early detection of psychiatric disorders The focus of the agreement is for exploring adolescence’s neurobiology for the […]readmore
Shots: BI to get rights to develop and commercialize bacteriophage lysins using Bioharmony ‘s technology for multi-drug resistant (MDR) Acinetobacter infections caused by Acinetobacter baumannii The focus of the collaboration is […]readmore